目的：以美国ＭａｒｉｏｎＭｅｒｅｌＤｏｗ．Ｉｎｃ．的地尔硫卓缓释胶囊（ＣａｒｄｉｚｅｍＳＲ９０ｍｇ）为对照，考察印度Ｔｏｒｒｅｎｔ公司生产的定尔心缓释片（ＤｉｌｚｅｍＳＲ９０ｍｇ）的相对生物利用度和药代动力学参数。方法：采用自身对照法进行单剂量和多剂量给药，血样经预处理后采用高效液相色谱法测定浓度。结果：用ＣＲＦ１程序处理，定尔心缓释片的ｔ１／２（Ｋａ）＝０．５７ｈ，ｔ１／２（Ｋｅ）＝４．０１ｈ，Ｔｍａｘ＝２．２７ｈ，Ｃｍａｘ＝５０．６１ｎｇ／ｍｌ，ＡＵＣ＝４０７．１９ｎｇ·ｈ／ｍｌ，相对生物利用度Ｆ＝９０．２％，多剂量给药达稳态波动系数为０．７１。结论：定尔心缓释片的相对生物利用度符合《新药（西药）临床研究指导原则汇编》的要求 Objective: To the United States MarionMerelDow. Inc. Of diltiazem sustained-release capsules (Cardizem SR90mg) as a control to investigate the relative bioavailability and pharmacokinetic parameters of Dilzem SR90mg manufactured by Torrent Corporation in India. Methods: The single-dose and multi-dose administration were carried out by self-control method. The blood samples were pretreated and determined by high performance liquid chromatography. Results: With the CRF1 program, t1 / 2 (Ka) = 0.57h, t1 / 2 (Ke) = 4.01h, Tmax = 2.27h and Cmax = 50.61ng / AUC = 407.19 ng · h / ml, relative bioavailability F = 90.2%, and the multi-dose administration reached a steady-state fluctuation coefficient of 0.71. Conclusion: The relative bioavailability of Ding Er Xin sustained-release tablets conforms to the compilation of Guiding Principles of Clinical Research of New Drugs (Western Medicine)